Search for: ""Daubert v. Merrell Dow Pharmaceuticals, Inc." OR "509 U.S. 579""
Results 21 - 40
of 112
Sorted by Relevance
|
Sort by Date
24 Jan 2014, 4:00 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993). [read post]
27 Mar 2009, 7:00 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993)). [read post]
23 Mar 2012, 1:59 pm
Merrell Dow Pharmaceutical, Inc., 509 U.S. 579 (1993) and its progeny. [read post]
28 Dec 2019, 4:00 am
Merrell Dow Pharmaceuticals Inc., 509 U.S. 579 (1993). [read post]
15 May 2008, 1:45 pm
Merrell Dow Pharmaceuticals, Inc. 509 U.S. 579 (1993). [read post]
1 Oct 2020, 5:00 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), the Frye test was the predominant standard for the admissibility of scientific evidence in state and federal courts. [read post]
17 Jun 2022, 2:09 pm
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), legal scholars, judges, and lawyers have struggled with the structure and validity of expert opinion on specific causation. [read post]
17 Mar 2014, 6:57 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993). [read post]
25 Feb 2009, 4:47 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993). [read post]
13 May 2011, 1:44 pm
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993). [read post]
13 Feb 2013, 10:52 am
Merrell Dow Pharmaceuticals Inc., 509 U.S. 579, 597 (1993). [read post]
29 Jan 2022, 6:24 pm
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 113 S.Ct. 2786, 125 L.Ed.2d 469 (1993), Fed.Rules, Evid.Rules 104(a), 702. [read post]
22 Feb 2011, 7:27 pm
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), in analyzing the expert presentations relating to the Rule 23 requirements, Plaintiffs contend that the Ninth Circuit found this to be no abuse of discretion, and that it did not matter because the district court judge was "guided by Daubert," concluded that the expert opinions were "based on valid principles," and were "sufficiently probative"… [read post]
22 Feb 2011, 7:27 pm
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), in analyzing the expert presentations relating to the Rule 23 requirements, Plaintiffs contend that the Ninth Circuit found this to be no abuse of discretion, and that it did not matter because the district court judge was "guided by Daubert," concluded that the expert opinions were "based on valid principles," and were "sufficiently probative" of the Rule 23 requirements. [read post]
31 Dec 2009, 2:34 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), and its federal and state progeny. [read post]
7 Feb 2009, 10:24 pm
Merrell Dow Pharmaceuticals Inc., 509 U.S. 579 (1993); see also Weisgram v. [read post]
5 Nov 2008, 8:48 pm
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993)] analysis. [read post]
25 Jan 2012, 6:42 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 113 S.Ct. 2786 (1993), and discussed in Taylor v. [read post]
24 Jan 2013, 8:09 am
Merrell Dow Pharmaceuticals, Inc. (509 U.S. 579), federal courts have applied a different standard. [read post]
6 Apr 2021, 2:30 pm
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993). [read post]
